GRC and Total Data Centre Solutions Partner to Expand Data Centre Liquid Immersion Cooling in Europe
20.10.2020 09:00:00 EEST | Business Wire | Press release
GRC (Green Revolution Cooling), the single-phase immersion-cooling authority® for data centres, today announces a new partnership contract with Total Data Centre Solutions (TDCS), a leading provider of mission critical and innovative infrastructure solutions for Data Centres throughout Europe and the Nordic region focused on carbon reduction and energy efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005928/en/
GRC ICEraQ immersion-cooling system with rack-mounted service rails for easy maintenance and hot swaps. (Photo: Business Wire)
Through the partnership, TDCS will act as the agent for GRC in Europe, selling GRC’s ICEraQ® Micro-Modular, Rack-Based Immersion-Cooling Systems and ICEtank® Modular, Containerised data centres to clients primarily in the UK, the Nordic region, Germany and Luxembourg. Additionally, this new partnership now enables GRC to engage and support European data centre customers with a local European presence.
“GRC is delighted to partner with TDCS,” said Jim Weynand, Chief Revenue Officer, GRC. “The proliferation of AI, 5G, Edge computing, reduced carbon emissions, and more throughout Europe present new challenges for both legacy and new data centre builds. Our partnership with TDCS will ensure clients throughout Europe can seamlessly integrate immersion cooling into their existing infrastructures.”
After thoroughly assessing various immersion cooling solutions on the market, TDCS recognized that GRC’s immersion-cooling technology is a differentiator that brings value to their existing and potential clients. European clients can now acquire GRC’s immersion-cooling systems through TDCS in order to reduce energy use or power consumption, solve power and space density challenges, cut energy cooling costs significantly and place HPC compute close to where it’s needed and secure other benefits of GRC’s game-changing immersion-cooling solutions. Being the longest established immersion cooling company, with 11+ years’ experience and many blue-chip clients including The US Government, the US Air Force, and approved by most global server manufacturers – take out the fan and reap all the awards.
“It’s exciting to build this new partnership with GRC,” said Jonathan Evans, Founder of TDCS. “Joining GRC as an agent partner is an opportunity for us to offer clients best-of-breed single-phase liquid immersion cooling technology. We are passionate about reducing the carbon footprint and the OpEx of each, of our clients. The partnership of GRC and TDCS helps solve carbon and cost issues facing all data center owners and operators, which perfectly complements our sustainability portfolio of offerings from technologies to data centres."
About GRC
GRC is the immersion cooling authority®. The company's patented immersion-cooling technology radically simplifies deployment of data centre cooling infrastructure. By eliminating the need for chillers, CRACs, air handlers, humidity controls and other conventional cooling components, enterprises reduce their data centre design, build, energy, and maintenance costs. GRC’s solutions are deployed in seventeen countries and are ideal for next-gen applications platforms, including artificial intelligence, blockchain, HPC, 5G, and other Edge Computing and core applications. Their systems are environmentally resilient, sustainable, and space saving, making it possible to deploy the solution in virtually any location with minimal lead time. Visit http://grcooling.com for more information.
About Total Datacentre Solutions
TDCS is an End to End Data Centre Consultancy, founded in 2002. Specialising in reducing a client’s IT carbon footprint and CapEx/OpEx with new technologies. TDCS comprises a team of data centre business professionals, many with 30+ years of industry experience. Our aim is to provide clients with innovative technologies to help reduce their carbon footprints and optimize their CapEx/OpEx. Visit https://www.totaldatacentresolutions.co.uk for more information
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005928/en/
Contact information
Milldam Public Relations
Adam Waitkunas
978-828-8304 (mobile)
adam.waitkunas@milldampr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom